Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. (formerly BioZone Pharmaceuticals, Inc.) on March 18, 2014. The report details a corporate restructuring event where BioZone Pharmaceuticals, Inc., a Nevada corporation, merged into its wholly-owned Delaware subsidiary, Cocrystal Pharma, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on the corporate merger and name change.
Material Changes
- Corporate Name: The issuer's name changed from BioZone Pharmaceuticals, Inc. to Cocrystal Pharma, Inc.
- Capitalization: There was no change in outstanding capitalization.
- Shareholder Impact: All common and preferred shareholders retained the exact same number of shares. All options and warrants were converted in the same manner.
- Trading Symbol: Pending approval from the Financial Industry Regulatory Authority (FINRA), the common stock continues to trade under the prior symbol "BZNE".
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary contingency noted is the pending approval from FINRA required to update the trading symbol from BZNE to reflect the new corporate name.
Investor Verification Checklist
- Verify the status of the FINRA approval for the trading symbol change.
- Confirm that the new ticker symbol has been assigned and is active on the exchange.
- Review subsequent filings for the first financial report under the new Cocrystal Pharma, Inc. name.